β-amyloid peptide as a target for treatment of Alzheimer's disease

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 4, 2002, Pages 503-512

  Conde, Santiago ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

Alzheimer's disease; Amyloid; Amyloid precursor protein (APP); Immunisation; Presenilin; Secretase; Senile plaque

Indexed keywords

ALPHA SECRETASE; ALZHEIMER DISEASE VACCINE; AMINO ACID; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTHRACYCLINONE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BENZOFURAN DERIVATIVE; BENZOIC ACID DERIVATIVE; BETA SECRETASE; CARBOXYLIC ACID DERIVATIVE; CHOLYLPENTAPEPTIDE; CONGO RED; ENZYME INHIBITOR; FURAN DERIVATIVE; GAMMA SECRETASE; HYDRAZIDE DERIVATIVE; ISOCHROMAN DERIVATIVE; L 685458; LETEPRINIM; NITRONE DERIVATIVE; OM99 2; PEPTIDE DERIVATIVE; PPI 368; PROTEIN ANTIBODY; PROTEINASE; SULFONIC ACID DERIVATIVE; THIOFLAVINE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IMMUNIZATION; MICROGLIA; MOUSE; NEUROTOXICITY; NONHUMAN; PROTEIN CONFORMATION; PROTEIN PROCESSING; REVIEW; SENILE PLAQUE;

EID: 0036222552     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.4.503     Document Type: Review

References (54)

1. Amyloid β peptide: A century of discoveries
2. Alzheimer's disease and Down's syndrome: Sharing a unique cerebrovascular amyloid fibril protein
3. Amyloid β-protein and the genetics of Alzheimer's disease
4. Therapeutic approaches to Alzheimer's disease
5. β-Amyloid therapies in Alzheimer's disease
6. Degradation of amyloid-β peptide: A key to Alzheimer pathogenesis, prevention and therapy
7. Effects of nicotine on APP secretion and Aβ- or CT(105)-induced toxicity
8. Translating cell biology into therapeutic advances in Alzheimer's disease
9. Effect of a memory-enhancing drug, AIT-082, on the level of synaptophysin
10. Amyloid-β-peptide reduces copper (II) to copper (I) independent of its aggregation state
11. In search of an enzyme: The β-secretase of Alzheimer's disease is an aspartic proteinase
12. BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein
13. Design of potent inhibitors for human brain memapsin 2 (β-secretase)
14. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor
15. Structure-based design: Potent inhibitors for human brain memapsin 2 (β-secretase)
16. Secretase inhibitors as therapeutics for Alzheimer's disease
17. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
18. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity
19. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
20. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing
21. A partner for presenilin
22. γ-secretase inhibitors repress thymocyte development
23. The neurotoxic carboxy-terminal fragment of the Alzheimer amyloid precursor binds specifically to a neuronal cell surface molecule: pH dependence of the neurotoxicity and the binding
24. A combinatorial approach to the identification of dipeptide aldehyde inhibitors of β-amyloid production
25. A substrate-based difluoroketone selectively inhibits Alzheimer's γ-secretase activity
26. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid β-protein precursor γ-secretase activity
27. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain
28. Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease
29. Experimental and clinical methods in the development of anti-Alzheimer drugs
30. Aging renders the brain vulnerable to amyloid β-protein neurotoxicity
31. Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins
32. β-Amyloid aggregation inhibitors for the treatment of Alzheimer's disease: Dream or reality?
33. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red
34. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution
35. A short synthesis of the β-amyloid (Aβ) aggregation inhibitor 3-p-toluoyl-2-[4′-(3-diethyl-aminopropoxy)-phenyl]-benzofuran
36. Protein misfolding and disease: Protein refolding and therapy
37. Inhibiting the conversion of soluble amyloid-β peptide into abnormally folded amyloidogenic intermediates: Relevance for Alzheimer's disease therapy
38. Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization
39. Modified-peptide inhibitors of amyloid β-peptide polymerization
40. A strategy for designing inhibitors of β-amyloid toxicity
41. Recognition sequence design for peptidyl modulators of β-amyloid aggregation and toxicity
42. Disaggregation of Alzheimer β-amyloid by site-directed mAb
43. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
44. Correlative memory deficits, Aβ elevation and amyloid plaques in transgenic mice
45. Two amyloid precursor protein transgenic mouse models with Alzheimer's disease-like pathology
46. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695
47. Vaccination for the prevention and treatment of Alzheimer's disease
48. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
49. Peptide immunization. A possible new treatment for Alzheimer's disease
50. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease
51. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
52. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
53. Immunisation with nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice
54. Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum?